ZOLADEX- goserelin acetate implant Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

zoladex- goserelin acetate implant

a-s medication solutions - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. zoladex is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see dosage and administration (2.3) and clinical studies (14.3)]. zoladex is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see dosage and administration (2.4) and cl

Zoladex Goserelin 3.6mg (as acetate) Implant syringe Australia - engleză - Department of Health (Therapeutic Goods Administration)

zoladex goserelin 3.6mg (as acetate) implant syringe

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer , where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m+) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, zoladex shrinks the lesions and reduces the symptoms, including pain. zoladex also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce

Zoladex 3.6mg Implant Malta - engleză - Medicines Authority

zoladex 3.6mg implant

astrazeneca uk limited - goserelin - implant - goserelin - endocrine therapy

Zoladex LA 10.8mg Implant Malta - engleză - Medicines Authority

zoladex la 10.8mg implant

astrazeneca uk limited - goserelin - implant - goserelin - endocrine therapy

DECAPEPTYL triptorelin acetate 100 micrograms/1 mL solution for injection in 1mL pre-filled syringe with integrated needle Australia - engleză - Department of Health (Therapeutic Goods Administration)

decapeptyl triptorelin acetate 100 micrograms/1 ml solution for injection in 1ml pre-filled syringe with integrated needle

ferring pharmaceuticals pty ltd - triptorelin acetate, quantity: 100 microgram (equivalent: triptorelin, qty 95.6 microgram/ml) - injection, solution - excipient ingredients: glacial acetic acid; water for injections; sodium chloride - decapeptyl 100 micrograms/1 ml is indicated for down-regulation and prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (art).,in clinical trials decapeptyl 100 micrograms/1 ml has been used in cycles where urinary and recombinant human follicle stimulating hormone (fsh) as well as human menopausal gonadotrophin (hmg) were used for stimulation.

ZOLADEX 10.8 IMPLANT goserelin 10.8mg (as acetate) implant syringe Australia - engleză - Department of Health (Therapeutic Goods Administration)

zoladex 10.8 implant goserelin 10.8mg (as acetate) implant syringe

astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer , where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.

Zoladex 3.6mg Implant Malta - engleză - Medicines Authority

zoladex 3.6mg implant

astrazeneca ab se-151 85, södertälje, sweden - goserelin - implant - goserelin 3.6 mg - endocrine therapy

Zoladex LA 10.8mg Implant Malta - engleză - Medicines Authority

zoladex la 10.8mg implant

astrazeneca ab se-151 85, södertälje, sweden - goserelin - implant - goserelin 10.8 mg - endocrine therapy

ZOLADEX LA DEPOT INJECTION 10.8 mgsyringe Singapore - engleză - HSA (Health Sciences Authority)

zoladex la depot injection 10.8 mgsyringe

astrazeneca singapore pte ltd - goserelin - injection - 10.8 mg/syringe - goserelin 10.8 mg/syringe

Zoladex 3.6 mg implant Irlanda - engleză - HPRA (Health Products Regulatory Authority)

zoladex 3.6 mg implant

astrazeneca ab - goserelin - implant - 3.6 milligram(s) - gonadotropin releasing hormone analogues; goserelin